Practical psychopharmacology updates for mental health clinicians. Useful for psychiatry / mental health professionals. Expert interviews and soundbites from CME presentations. Practical and free of commercial bias. Not sponsored by any pharmaceutical company.
The Psychopharmacology and Psychiatry Updates podcast is a fantastic resource for anyone interested in staying up to date with current and relevant treatment information in the field of mental health. I have found that listening to this podcast is a wonderful way to end the day, as it provides valuable insights and knowledge that can be applied to real-world scenarios.
One of the best aspects of this podcast is the expertise of the speakers. Each episode features professionals who are well-versed in their respective fields, providing listeners with reliable and evidence-based information. This ensures that the information presented is accurate and trustworthy, giving listeners confidence in what they are learning.
Another great aspect of this podcast is its format. The episodes are short, typically lasting around 20 minutes or less. This makes it easy to fit them into a busy schedule, such as during a commute or while taking a break. Despite their brevity, each episode manages to cover a variety of topics, ensuring that listeners receive a well-rounded education on psychopharmacology and psychiatry.
Furthermore, the podcast does not overwhelm its listeners with complex jargon or technical terms. The episodes are presented in an accessible manner, making it easy for both professionals and students alike to understand and absorb the information being shared. This is particularly helpful for PMHNP students like myself who may be new to certain concepts or medications.
While there are many positive aspects of The Psychopharmacology and Psychiatry Updates podcast, one potential downside is that it may not delve deep enough into certain topics for those seeking more comprehensive information. Given the short duration of each episode, only a limited amount of content can be covered. However, this can also be seen as a strength for those looking for quick updates or refreshers rather than in-depth discussions.
In conclusion, The Psychopharmacology and Psychiatry Updates podcast is an invaluable resource for anyone interested in learning about current treatment information in mental health. With its knowledgeable speakers, concise format, and accessible language, it provides listeners with a convenient way to stay informed and up to date. Whether you are a professional or a student in the field, this podcast is definitely worth a listen.
In this episode, we explore the potentially fatal side effects of clozapine that often receive less attention than agranulocytosis: bowel obstruction and pneumonia. Could your vigilant monitoring of blood counts be overshadowing equally dangerous risks? Faculty: Oliver Freudenreich, M.D. Host: Richard Seeber, M.D. Learn more about our membership here Earn 0.5 CME: Quick Take Vol. 69 Clozapine: The Hidden Risks of Ileus and Pneumonia
In this episode, we discuss evidence-based strategies for safely tapering patients off benzodiazepines, including cut-and-hold and microtapering techniques. What's the best approach when commercial dosage forms limit gradual reductions? Faculty: Alexis Ritvo Host: Richard Seeber, M.D. Learn more about our memberships here Earn 1.25 CME: Strategies for Successful Benzodiazepine Deprescribing Techniques for Successful Benzodiazepine Tapering
In this episode, we explore lithium's surprising positive effect on bone mineral density in patients with bipolar disorder. Could the medication many psychiatrists use as a mood stabilizer also be protecting patients from osteoporosis? Faculty: Paul Zarkowski, M.D. Host: Richard Seeber, M.D. Learn more about our membership here Earn 0.5 CME: Quick Take Vol. 68 Can Lithium Protect Against Osteoporosis?
In this episode, we explore evidence-based strategies for successful benzodiazepine tapering with addiction psychiatrist Dr. Alexis Ritvo. How can clinicians minimize withdrawal effects while supporting patients through this challenging process? Faculty: Alexis Ritvo, M.D. Host: Richard Seeber, M.D. Learn more about our membership here Earn 1.25 CMEs: Strategies for Successful Benzodiazepine Deprescribing Understanding the Principles of Benzodiazepine Tapering
In this episode, we explore compelling evidence from the UK Biobank showing how vitamin D deficiency may increase dementia risk by up to 25%. Could this affordable supplement be an essential piece of your brain health strategy? Faculty: Scott Beach, M.D. Host: Richard Seeber, M.D. Learn more about our membership here Earn 0.5 CME: Quick Take Vol. 68 Can Vitamin D Deficiency Increase the Risk of Alzheimer's Disease?
In this episode, we explore the complex process of benzodiazepine deprescribing, examining when and how to help patients reduce or discontinue these medications. How can clinicians balance the benefits of deprescription against the challenges of withdrawal? Faculty: Alexis Ritvo, M.D. Host: Richard Seeber, M.D. Learn more about our memberships here Earn 1.25 CMEs: Strategies for Successful Benzodiazepine Deprescribing Benzodiazepine Deprescription: Indications, Benefits, and Risks
In this episode, we explore the unique considerations for using long-acting injectable antipsychotics in women with schizophrenia. How might hormonal fluctuations throughout a woman's life impact treatment decisions for schizophrenia? Faculty: Oliver Freudenreich, M.D. Host: Richard Seeber, M.D. Learn more about our membership here Earn 0.5 CME: Quick Take Vol. 68 Long-Acting Antipsychotics: An Option for Women with Schizophrenia?
In this episode, we explore the challenges and current guidelines for benzodiazepine use in pregnancy, breastfeeding, and adolescence. When is it appropriate to continue benzodiazepines during pregnancy, and what alternatives should clinicians consider? Faculty: Alexis Ritvo, M.D. Host: Richard Seeber, M.D. Learn more about our memberships here Earn 1 CME: Understanding Benzodiazepine Prescribing: A Clinician's Guide Consequences of Benzodiazepine Use in Pregnancy, Breastfeeding, and Adolescence
In this episode, we explore benzodiazepine use disorder, distinguishing between physical dependence and addiction while examining practical strategies for safe prescribing. Did you know only 1.5% of benzodiazepine users actually develop a use disorder? Faculty: Alexis Ritvo, M.D. Host: Richard Seeber, M.D. Learn more about our memberships here Earn 1 CME: Understanding Benzodiazepine Prescribing: A Clinician's Guide Benzodiazepine Use Disorder
In this episode, we explore the potential role of the probiotic Akkermansia muciniphila in managing olanzapine-induced weight gain. Could this tiny gut bacterium be the key to maintaining metabolic health while on antipsychotics? Faculty: Oliver Freudenreich, M.D. Host: Richard Seeber, M.D. Learn more about our membership here Earn 0.5 CME: Quick Take Vol. 67 Olanzapine-Induced Weight Gain: Can Akkermansia Muciniphila Help?
In this episode, we explore the dangerous risks of benzodiazepine use, focusing on the potentially lethal combination with opioids, cognitive impairment, increased accident risk, and fall hazards. Did you know that benzodiazepines combined with opioids increase overdose risk fivefold in the first 90 days? Faculty: Alexis Ritvo, M.D. Host: Richard Seeber, M.D. Learn more about our memberships here Earn 1 CME: Understanding Benzodiazepine Prescribing: A Clinician's Guide Understanding the Major Risks of Benzodiazepine Use
In this episode, we explore the latest research on antidepressant discontinuation symptoms, revealing that about 14% of patients experience these effects when stopping medication. Which antidepressants are most likely to cause these "brain zaps" and other withdrawal symptoms? Faculty: Scott Beach, M.D. Host: Richard Seeber, M.D. Learn more about our membership here Earn 0.5 CME: Quick Take Vol. 67 Which Antidepressants Have the Highest Risk of Discontinuation Symptoms?
In this episode, we discuss the appropriate use of benzodiazepines, focusing on evidence-based indications and optimal medication selection. Did you know that alprazolam has unique properties that make it more addictive than other benzodiazepines? Faculty: Alexis Ritvo, M.D. Host: Richard Seeber, M.D. Learn more about our memberships here Earn 1 CME: Understanding Benzodiazepine Prescribing: A Clinician's Guide Appropriate Benzodiazepine Use: Indications and Optimal Selection
In this episode, we explore the evidence behind Transcranial Magnetic Stimulation (TMS) for depression, from early clinical trials to real-world effectiveness. What makes some patients respond better to TMS than others? We discuss response rates, treatment protocols, and the exciting development of faster treatment options. Faculty: Simon Kung, M.D. Host: Richard Seeber, M.D. Learn more about our memberships here Earn 1 CME: TMS in Psychiatry: Innovations and Best Practices Exploring the Evidence of TMS for Depression
In this episode, we explore the crucial aspects of patient selection for Transcranial Magnetic Stimulation (TMS) in treating depression. We discuss insurance criteria, contraindications, and practical considerations. Did you know that while TMS was FDA-approved in 2008, it wasn't widely accessible until Medicare began covering it in 2014? Faculty: Simon Kung, M.D. Host: Richard Seeber, M.D. Learn more about our memberships here Earn 1 CME: TMS in Psychiatry: Innovations and Best Practices Optimizing Patient Selection for TMS Treatment
In this episode, we explore a landmark Finnish study examining the long-term risk of agranulocytosis in patients taking clozapine. The research followed 62,000 patients over 22 years, providing crucial data about this rare but serious side effect. Could these findings change how we approach clozapine prescribing and monitoring requirements? Faculty: Oliver Freudenreich, M.D. Host: Richard Seeber, M.D. Learn more about our membership here Earn 0.75 CME: Quick Take Vol. 66 Does Clozapine's Agranulocytosis Risk Persist Beyond Initial Treatment Period?
In this episode, we explore Transcranial Magnetic Stimulation (TMS) as a treatment option for Obsessive-Compulsive Disorder (OCD). We discuss the FDA-approved devices, unique protocols, and why patients need their anxiety triggered before each session. Did you know TMS for OCD targets a completely different brain region than TMS for depression? Faculty: Simon Kung, M.D. Host: Richard Seeber, M.D. Learn more about our memberships here Earn 1 CME: TMS in Psychiatry: Innovations and Best Practices Exploring the Evidence of TMS for OCD
In this episode, we explore donanemab, a groundbreaking monoclonal antibody treatment for Alzheimer's disease. We discuss its efficacy in reducing beta-amyloid plaques, unique treatment duration protocol, and safety considerations. Could this time-limited treatment approach revolutionize how we manage Alzheimer's progression? Faculty: Scott Beach, M.D. Host: Richard Seeber, M.D. Learn more about our membership here Earn 0.75 CMEs: Quick Take Vol. 66 Can Donanemab Slow Alzheimer's Progression?
In this episode, we explore a groundbreaking Danish registry study that challenges common beliefs about long-term benzodiazepine use and dose escalation patterns. Are our concerns about inevitable tolerance and dependence justified? The study's findings might surprise you and reshape prescribing practices. Faculty: Scott Beach, M.D. Host: Richard Seeber, M.D. Learn more about our membership here Earn 0.75 CME: Quick Take Vol. 65 Do Benzodiazepine Users Escalate Doses Over Time?
In this episode, we explore the side effects and safety considerations of Transcranial Magnetic Stimulation (TMS) therapy in psychiatry. Did you know that despite common concerns, fewer than 2% of patients discontinue TMS due to discomfort? We'll discuss everything from common side effects to practical management strategies. Faculty: Simon Kung, M.D. Host: Richard Seeber, M.D. Learn more about our memberships here Earn 1 CME: TMS in Psychiatry: Innovations and Best Practices Assessing the Potential Side Effects of TMS
In this episode, we explore the crucial interaction between SSRIs and oral anticoagulants, examining a groundbreaking 23-year study of over 330,000 patients. Does combining these medications significantly increase bleeding risk, and if so, how can we safely manage patients who need both treatments? Faculty: Scott Beach, M.D. Host: Richard Seeber, M.D. Learn more about our membership here Earn 0.75 CME: Quick Take Vol. 65 Can SSRIs Be Safely Prescribed With Oral Anticoagulants?
In this episode, we explore the safe use and monitoring of lamotrigine, focusing on cardiac risks and when EKG monitoring is necessary. Did you know that reducing lamotrigine dose doesn't actually mitigate cardiac risks but could increase the risk of psychiatric destabilization? Faculty: Scott Beach, M.D. Host: Richard Seeber, M.D. Learn more about our memberships here Earn 0.5 CME: Lamotrigine: From Current Indications to Cardiac Side Effects Strategies for Safe Usage and Proper Monitoring of Lamotrigine
In this episode, we explore the often-overlooked phenomenon of antipsychotic withdrawal, examining new findings from the world's largest drug safety database. Could some cases of apparent psychotic relapse actually be withdrawal symptoms in disguise? We discuss common withdrawal effects, risk factors, and evidence-based strategies for safe medication discontinuation. Faculty: Oliver Freudenreich, M.D. Host: Richard Seeber, M.D. Learn more about our membership here Earn 0.75 CME: Quick Take Vol. 64 Antipsychotic Withdrawal Syndrome: Symptoms, Risks, and Prevention Strategies
In this episode, we explore lamotrigine's cardiac side effects, focusing on QTc prolongation and QRS widening. How concerned should psychiatrists be about the FDA warning regarding lamotrigine's cardiac effects? We examine the evidence behind these concerns and discuss practical implications for clinical practice. Faculty: Scott Beach, M.D. Host: Richard Seeber, M.D. Learn more about our memberships here Earn 0.5 CME: Lamotrigine: From Current Indications to Cardiac Side Effects Lamotrigine Effect on QTc Prolongation and QRS Widening
In this episode, we examine a groundbreaking Danish study that challenges the conventional belief that sedative medications increase fall risk in older adults. Could untreated insomnia, rather than the medications used to treat it, be the real culprit behind falls in elderly patients? Faculty: Scott Beach, M.D. Host: Richard Seeber, M.D. Learn more about our membership here Earn 0.75 CME: Quick Take Vol. 64 Insomnia in the Elderly: Do Sedatives Increase or Decrease Fall Risk?
In this episode, we explore lamotrigine's side effects and special considerations, particularly focusing on identifying dangerous skin reactions, pregnancy considerations, and overdose risks. Did you know that Asian populations may require special genetic screening before starting lamotrigine due to increased skin reaction risks? Faculty: Scott Beach, M.D. Host: Richard Seeber, M.D. Learn more about our memberships here Earn 0.5 CME: Lamotrigine: From Current Indications to Cardiac Side Effects Lamotrigine: Side Effects and Special Considerations
In this episode, we explore the efficacy and safety of iloperidone in treating bipolar disorder, examining new phase 3 trial data that reveals both promising results for mania symptoms and important considerations about side effects. Can this antipsychotic's favorable EPS profile outweigh its metabolic risks? Faculty: Paul Zarkowski, M.D. Host: Richard Seeber, M.D. Learn more about our membership here Earn 0.75 CMEs: Quick Take Vol. 63 Iloperidone: A Potential Treatment Option for Bipolar Mania
In this episode, we explore the vital aspects of prescribing lamotrigine, from its mechanisms to titration schedules. Did you know that birth control pills can cut lamotrigine levels in half within just one week? Understanding these interactions is crucial for safe and effective treatment. Faculty: Scott Beach, M.D. Host: Richard Seeber, M.D. Learn more about our memberships here Earn 0.5 CME: Lamotrigine: From Current Indications to Cardiac Side Effects Understanding Lamotrigine Mechanisms and Titration Schedule
In this episode, we explore the pharmacological management of agitation in emergency settings, focusing on benzodiazepines and the novel medication dexmedetomidine. Did you know there's now a sublingual option that works through an entirely different mechanism than traditional anti-agitation medications? Faculty: Scott Zeller, M.D. Host: Richard Seeber, M.D. Learn more about our memberships here Earn 1.25 CME: The Psychopharmacology of Agitation: Managing Behavioral Emergencies The Role of Benzodiazepines and Dexmedetomidine in Managing Agitation
In this episode, we explore KarXT, a groundbreaking experimental antipsychotic that works through the cholinergic system rather than dopamine pathways. Could this novel approach revolutionize schizophrenia treatment by offering similar efficacy to current antipsychotics but without the motor side effects? Faculty: Oliver Freudenreich, M.D. Host: Richard Seeber, M.D. Learn more about our membership here Earn 0.75 CMEs: Quick Take Vol. 63 Xanomeline-Trospium (KarXT) Shows Efficacy in Phase 3 Trial for Schizophrenia
In this episode, we explore evidence-based pharmacologic strategies for managing acute agitation in emergency settings, challenging the stigmatizing concept of “chemical restraints” and providing practical approaches to achieve optimal patient outcomes. Did you know that many agitated patients can actively participate in medication decisions, even during a crisis? Faculty: Scott Zeller, M.D. Host: Richard Seeber, M.D. Learn more about our memberships here Earn 1.25 CME: The Psychopharmacology of Agitation: Managing Behavioral Emergencies Pharmacologic Strategies for Managing Agitation: General Recommendations and Treatments Goals
In this episode, we explore how famotidine, a common heartburn medication, might help treat post-COVID brain fog. New research suggests this H2 blocker could improve cognitive function in recovering patients. But how does a stomach acid reducer potentially clear mental haziness? Faculty: Scott Beach, M.D. Host: Richard Seeber, M.D. Learn more about our membership here Earn 0.5 CMEs: Quick Take Vol. 62 Famotidine for COVID-19 Brain Fog: A Promising Treatment Option
In this episode, we explore nonpharmacologic strategies for managing agitated patients, focusing on verbal de-escalation techniques. Did you know that using physical restraints adds an average of four hours to an emergency department stay? Dr. Scott Zeller shares evidence-based approaches to transform crisis intervention in emergency settings. Faculty: Scott Zeller, M.D. Host: Richard Seeber, M.D. Learn more about our memberships here Earn 1.25 CME: The Psychopharmacology of Agitation: Managing Behavioral Emergencies Nonpharmacologic Strategies for Managing Agitation: Verbal De-Escalation
In this episode, we explore the RADAR trial's findings on antipsychotic dose reduction in schizophrenia. Can patients with chronic schizophrenia safely reduce or discontinue their antipsychotic medications without increasing relapse risk? The trial's results challenge common assumptions about medication reduction and provide crucial guidance for clinical practice. Faculty: Oliver Freudenreich, M.D. Host: Richard Seeber, M.D. Learn more about our membership here Earn 0.5 CME: Quick Take Vol. 62 Antipsychotic Dose Reduction in Schizophrenia: Insights From the RADAR Trial
In this episode, we explore the challenges of diagnosing and managing agitation in emergency settings, focusing on mood disorders and substance use. Dr. Scott Zeller shares insights on differentiating acute mania from substance-induced psychosis. How can clinicians navigate the complex interplay between psychiatric symptoms and substance effects in emergencies? Faculty: Scott Zeller, M.D. Host: Richard Seeber, M.D. Learn more about our memberships here Earn 1.25 CME: The Psychopharmacology of Agitation: Managing Behavioral Emergencies Other Psychiatric Diagnoses in Agitated Patients: Mood and Substance Use Disorders
In this episode, we explore the use of high-dose olanzapine as a potential alternative to clozapine for treatment-resistant schizophrenia. We discuss a systematic review that examines the efficacy and safety of olanzapine doses above the FDA-approved maximum. Could high-dose olanzapine be a viable option when patients refuse clozapine? Faculty: Oliver Freudenreich, M.D. Host: Richard Seeber, M.D. Learn more about our membership here Earn 0.5 CMEs: Quick Take Vol. 61 Is High-Dose Olanzapine an Option for Treatment-Resistant Schizophrenia?
In this episode, we explore how integrating psychodynamic principles into pharmacotherapy can enhance treatment outcomes. We discuss seven key features of psychodynamic psychotherapy and their application in routine psychiatric practice. How might understanding a patient's fantasies about their illness impact their response to medication? Faculty: David Mintz, M.D. Host: Richard Seeber, M.D. Learn more about our memberships here Earn 1 CME: Psychodynamic Psychopharmacology: Alliance, Communication, and Psychotherapy Skills Psychotherapy Skills in Everyday Practice: Ordinary Medical Psychotherapy
In this episode, we explore strategies for discontinuing benzodiazepines in hospitalized elderly patients. We discuss a recent Israeli study that tested two interventions during inpatient stays. Can a simple hospital-based intervention lead to successful long-term medication changes? Faculty: Paul Zarkowski, M.D. Host: Richard Seeber, M.D. Learn more about our membership here Earn 0.5 CMEs: Quick Take Vol. 61 Stopping Benzodiazepines and Z-Drugs in Hospitalized Elderly Patients
In this episode, we explore the critical role of therapeutic alliance in psychopharmacology. We discuss how factors like empathy, communication, and shared decision-making can significantly impact treatment outcomes. Did you know that a doctor's warm voice can increase appointment adherence by 162%? Faculty: David Mintz, M.D. Host: Richard Seeber, M.D. Learn more about our memberships here Earn 1 CME: Psychodynamic Psychopharmacology: Alliance, Communication, and Psychotherapy Skills Pharmacotherapy Alliance, Treatment Preferences, and Communication
In this episode, we explore the cardiac and metabolic safety profile of antipsychotics in youth, based on a World Health Organization Safety Database analysis. We discuss age-dependent risks, specific medication concerns, and the importance of monitoring. How can clinicians balance the benefits of antipsychotics with potential cardiometabolic risks in young patients? Faculty: David Rosenberg, M.D. Host: Richard Seeber, M.D. Learn more about our membership here Earn 0.5 CMEs: CAP Smart Takes Vol. 20 Cardiac and Metabolic Safety Profile of Antipsychotics in Youth
In this episode, we explore the unexpected consequences of promoting a purely biological view of mental illness. How does framing mental health conditions as solely biological affect stigma, patient outcomes, and physician empathy? We delve into the complex interplay between biological and psychosocial factors in mental health treatment. Faculty: David Mintz, M.D. Host: Richard Seeber, M.D. Learn more about our memberships here Earn 1 CME: Psychodynamic Psychopharmacology: Alliance, Communication, and Psychotherapy Skills The Biological Theory of Illness and Stigma
In this episode, we explore the bidirectional relationship between psychiatric disorders and cardiovascular disease, discussing a groundbreaking study involving over 900,000 subjects. We ask: Can a mental health diagnosis increase your risk of heart disease? Faculty: Scott Beach, M.D. Host: Richard Seeber, M.D. Learn more about our membership her Earn 0.5 CMEs: Quick Take Vol. 60 Psychiatric Disorders and Subsequent Risk of Cardiovascular Disease
In this episode, we explore the science behind the art of psychopharmacotherapy with Dr. David Mintz. We delve into how psychosocial factors, including the prescriber's approach, can significantly impact medication outcomes. Did you know that some psychiatrists achieve better results with placebos than others do with active medications? Faculty: David Mintz, M.D. Host: Richard Seeber, M.D. Learn more about our memberships here Earn 1 CME: Psychodynamic Psychopharmacology: Alliance, Communication, and Psychotherapy Skills The Science of the Art of Psychopharmacotherapy
In this episode, we explore the long-term effects of methylphenidate on sleep in children and adolescents with ADHD. Can stimulant medication actually improve sleep in ADHD patients? We dive into surprising research findings that challenge common assumptions about ADHD treatment and sleep disturbances. Faculty: David Rosenberg, M.D. Host: Richard Seeber, M.D. Learn more about our membership here Earn 0.5 CMEs: CAP Smart Takes Vol. 20 Long-Term Effects of Methylphenidate on Sleep in Children and Adolescents With ADHD
In this episode, we explore the strategic use of natural medications in psychiatry, focusing on combination therapies for various mental health conditions. Dr. David Mischoulon discusses potential synergies between natural remedies and conventional drugs, as well as all-natural combinations. But how do we balance efficacy with safety when using these less-studied treatments? Faculty: David Mischoulon, M.D. Host: Richard Seeber, M.D. Learn more about our memberships here Earn 0.75 CME: Natural Medication in Psychiatry: Focus on Versatile Agents and Combination Strategies Potential Combinations of Natural Medication for Psychiatric Disorders
In this episode, we explore the use of memantine in treating trichotillomania and skin picking disorder. Could this common Alzheimer's medication be the breakthrough we've been waiting for in managing body-focused repetitive behaviors? Dr. Bob Hudak discusses a promising study that offers new hope for patients struggling with these often-overlooked conditions. Faculty: Robert Hudak, M.D. Host: Richard Seeber, M.D. Learn more about our membership here Earn 0.5 CMEs: Quick Take Vol. 60 Efficacy of Memantine in Treating Trichotillomania and Skin-Picking Disorder
In this episode, we explore Ashwagandha, a versatile natural remedy in psychiatry. We discuss its potential applications in treating anxiety, depression, OCD, and other mental health disorders. Could this ancient herb be the key to managing treatment-resistant patients? Faculty: David Mischoulon, M.D. Host: Richard Seeber, M.D. Learn more about our memberships here Earn 0.75 CME: Natural Medication in Psychiatry: Focus on Versatile Agents and Combination Strategies Ashwagandha (ASW): Potential Indications and Administration in Psychiatric Disorders
In this episode, we explore the controversial use of electroconvulsive therapy (ECT) in adolescents with severe depression and suicidality. We discuss a study examining ECT's effectiveness, factors influencing outcomes, and its potential as a treatment option. Is ECT a viable last resort for treatment-resistant depression in teens? Faculty: David Rosenberg, M.D. Host: Richard Seeber, M.D. Learn more about our membership here Earn 0.5 CMEs: CAP Smart Takes Vol. 19 Electroconvulsive Therapy for Adolescents With Severe Depression and Suicidality
In this episode, we explore the potential uses of Cannabidiol (CBD) in psychiatric practice. We discuss its mechanisms, evidence for various disorders, and guidelines for safe use. Is CBD the next breakthrough in mental health treatment, or just another passing trend? Faculty: David Mischoulon, M.D. Host: Richard Seeber, M.D. Learn more about our memberships here Earn 0.75 CME: Natural Medication in Psychiatry: Focus on Versatile Agents and Combination Strategies Cannabidiol: Evidence for Psychiatric Disorders and Recommendations for Using It
In this episode, we explore the use of medical cannabis in treating Parkinson's disease. We discuss a retrospective study that reveals promising results for both motor and non-motor symptoms. Could medical cannabis be the versatile solution we've been seeking for Parkinson's treatment? Faculty: Gregory Pontone, M.D. Host: Richard Seeber, M.D. Learn more about our membership here Earn 0.5 CMEs: Quick Take Vol. 59 Medical Cannabis in the Treatment of Parkinson's Disease
In this episode, we explore the potential of N-acetylcysteine (NAC) in treating mood disorders. We discuss its mechanism of action, clinical evidence for its use in depression and bipolar disorder, and its possible benefits for both adults and children. Could this natural compound revolutionize our approach to mood stabilization? Faculty: David Mischoulon, M.D. Host: Richard Seeber, M.D. Learn more about our memberships here Earn 0.75 CME: Natural Medication in Psychiatry: Focus on Versatile Agents and Combination Strategies Exploring the Evidence of N-Acetyl-Cysteine (NAC) for Mood Disorders
© 2020-2025 Ivy Podcast Discovery LLC
